Seizures associated with Lennox-Gastaut syndrome
[adjunctive treatment with clobazam] (specialist use
only)
▶BY MOUTH
▶Adult: Initially 2.5 mg/kg twice daily for 1 week, then
increased to 5 mg/kg twice daily, then increased in
steps of 2.5 mg/kg twice daily, adjusted according to
response, dose to be increased at weekly intervals, food
may affect absorption (take at the same time with
respect to food); maximum 20 mg/kg per day
Seizures associated with Dravet syndrome [adjunctive
treatment with clobazam] (specialist use only)
▶BY MOUTH
▶Adult: Initially 2.5 mg/kg twice daily for 1 week, then
increased to 5 mg/kg twice daily, then increased in
steps of 2.5 mg/kg twice daily, adjusted according to
response, dose to be increased at weekly intervals, food
may affect absorption (take at the same time with
respect to food); maximum 20 mg/kg per day
PDF page 348
NICE decisions
▶Cannabidiol with clobazam for treating seizures associated
with Dravet syndrome (December 2019) NICE TA614
Cannabidiol (Epidyolex ®) with clobazam is recommended
as an option for treating seizures associated with Dravet
syndrome in patients aged 2 years and older, only if:
. the frequency of convulsive seizures is checked every
6 months, and cannabidiol is stopped if the frequency
has not fallen by at least 30% compared with the
6 months before starting treatment
. the manufacturer provides cannabidiol according to the
commercial arrangement.
Patients whose treatment was started within the NHS
before this guidance was published should have the option
to continue treatment, without change to their funding
arrangements, until they and their NHS clinician consider
it appropriate to stop.
www.nice.org.uk/guidance/ta614
▶Cannabidiol with clobazam for treating seizures associated
with Lennox–Gastaut syndrome (December 2019) NICE TA615
Cannabidiol (Epidyolex ®) with clobazam is recommended
as an option for treating seizures associated with Lennox-
Gastaut syndrome in patients aged 2 years and older, only
if:
. the frequency of drop seizures is checked every
6 months, and cannabidiol is stopped if the frequency
has not fallen by at least 30% compared with the
6 months before starting treatment,
. the manufacturer provides cannabidiol according to the
commercial arrangement.
Patients whose treatment was started within the NHS
before this guidance was published should have the option
to continue treatment, without change to their funding
arrangements, until they and their NHS clinician consider
it appropriate to stop.
www.nice.org.uk/guidance/ta615
PDF pages 348, 349
